Riv — Competitive Intelligence Brief

Riv (riv) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease Inhibitors. Area: Infectious Disease.

marketed Protease Inhibitors HIV-1 protease Infectious Disease Vaccine

Target snapshot

Riv (riv) — Pfizer.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Riv TARGET	riv	Pfizer	marketed	Protease Inhibitors	HIV-1 protease
Triple therapy with ritonavir	Triple therapy with ritonavir	Sociedad Andaluza de Enfermedades Infecciosas	marketed	HIV protease inhibitor	HIV-1 protease
TMC435	TMC435	Tibotec Pharmaceuticals, Ireland	phase 3	protease inhibitor	HIV-1 protease
TMC114	TMC114	Tibotec Pharmaceuticals, Ireland	phase 3	protease inhibitor	HIV-1 protease
abacavir/lamivudine + darunavir/ritonavir	abacavir/lamivudine + darunavir/ritonavir	University of Modena and Reggio Emilia	phase 3	NRTI + PI	HIV-1 reverse transcriptase, HIV-1 protease
Tipranavir/Ritonavir	Tipranavir/Ritonavir	Johns Hopkins University	phase 3	Protease inhibitor	HIV-1 protease
LPV	LPV	Bristol-Myers Squibb	phase 3	HIV protease inhibitor	HIV-1 protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease Inhibitors class)

1. Pfizer · 1 drug in this class